From engineering to millions of parts: How RPK Medical works with pharma and CMOs from day one

Medical device manufacturing is not a linear process. It's a chain of decisions, made early or made late, that determine whether a product reaches the market on time, within budget, and at the quality level that patients and regulators demand. At RPK Medical, we built our entire operation around one idea: the earlier we get involved, the better the outcome for everyone.

This article explains exactly how RPK Medical works with pharmaceutical companies, CMOs, and medical device OEMs, from the very first engineering conversation all the way through to producing millions of components a year at a global scale.

What RPK Medical actually makes

Before getting into the process, it's worth being specific about what RPK Medical engineers and manufactures, because our core technical competency shapes everything we do.

RPK Medical specializes in precision springs, metal strip components (produced via multislide and stamping processes), and contact parts for medical devices. These are not generic commodity parts. In medical applications, autoinjectors, pen injectors, inhalers, wearables, surgical staplers, syringes, and drug delivery systems, springs, and metal components are often the most mechanically critical elements in the entire device. They define actuation force, dose accuracy, device reliability, and patient safety.

This specialization forms our engineering credibility. When RPK Medical suggests design changes or material substitutions, it is grounded in decades of specialized expertise in component behavior across development, assembly, and use at scale.

Why the starting point matters more than most companies realize

Unlike most suppliers who wait for finalized designs, RPK Medical seeks early involvement, finding real value by joining the conversation before designs are set.

When our engineers collaborate with a client's R&D or product development team during the design phase, we can identify manufacturability issues before they become expensive problems. We can recommend materials that perform better in automated assembly. We can suggest geometry changes that reduce scrap rates without affecting clinical performance. We can flag tolerance stacks that look fine on paper but create headaches at high-volume production.

The result: fewer engineering change orders downstream, faster validation, and lower unit costs over the product's lifetime. Design-for-manufacturability isn't a buzzword at RPK Medical; it's how we protect our clients' schedules and budgets.

The real benefits of working with RPK Medical from day one

This is the part that pharma teams and CMOs consistently underestimate, and consistently appreciate once they've experienced it. Bringing RPK Medical in at the design stage, rather than at the procurement stage, delivers concrete, measurable advantages:

• Lower total cost of ownership. Design decisions made without manufacturing input are often expensive to undo. When RPK Medical engineers are in the room from the start, we eliminate cost drivers before they are designed in, optimizing material selection, tolerances, and component geometry for efficient, high-yield production at scale.
• Faster time to market. Early manufacturing involvement compresses the development timeline. Prototypes are built faster. Process development runs in parallel with design refinement rather than sequentially. Fewer redesign loops mean the path from concept to validated product is significantly shorter.
• Fewer surprises during scale-up. When the production process is designed alongside the product, not after it, industrialization goes smoothly. Yield rates, cycle times, and quality metrics are predictable because the line was engineered for this specific product from the beginning.
• Stronger regulatory position. RPK Medical's APQP-based development process generates the documentation trail required for regulatory submissions. Starting early means that quality planning, risk management, and process validation are built in from the ground up, not retrofitted under submission pressure.
• A single accountable partner. Rather than managing a fragmented supply chain of spring suppliers, stamping houses, and assembly operations, clients work with a single engineering partner that controls the entire value chain. One point of contact. One quality system. One set of documentation standards.
• Access to 50 years of application knowledge. RPK Medical has engineered springs and precision metal components for medical devices across virtually every drug delivery platform in use today. That institutional knowledge, applied at the design stage, prevents the kind of mistakes that only become visible after tooling has been cut.

Phase 1: Product Design

Every project starts with listening. Our engineering teams, working globally and connected in real time through our RPK Technological Center, work alongside client teams to understand the clinical need, regulatory pathway, target market, and production volume expectations.

From there, we apply advanced engineering tools, including FEM/FEA structural analysis, to predict how components will behave under real-world stress before a single prototype is built. For springs and metal strip components, this kind of analysis is particularly valuable: fatigue behavior, load-deflection curves, and relaxation characteristics can all be modeled and optimized computationally before committing to tooling. We use rapid prototyping, including in-house 3D printing, to deliver physical parts to clients quickly, accelerating design iteration cycles that would otherwise take weeks.

At this stage, our involvement is not just technical. It's strategic. We help clients make design decisions that are informed by what's actually achievable in manufacturing, not just what's theoretically possible in CAD.

Phase 2: Product and Process Development

Once the design is conceptually validated, the real engineering work begins. RPK Medical's development phase is where design becomes process and where the foundation for scalable, reliable production is built.

Our dedicated project management teams lead the client through a structured Advanced Product Quality Planning (APQP) process, ensuring that every step from prototype to production is documented, validated, and aligned with regulatory requirements, including ISO 13485.

We design and build our own machinery, tooling, multislide equipment, stamping lines, and automatic assembly lines in-house. This is a critical differentiator. Because we control the development of the production equipment ourselves, rather than outsourcing it, we can optimize machines specifically for each client's product. The result is tighter tolerances, higher yields, and assembly lines that are built to scale from day one rather than retrofitted later.

The development phase also includes:

• Prototyping and validation (IQ/OQ/PQ)
• Ramp-up planning
• Custom packaging design, including specialty formats for clean-room environments
• Process design and full documentation for regulatory submission support

For pharma clients with combination products or wearable drug-delivery systems, RPK Medical's expertise in precision components is most valuable at this phase; proper engineering now prevents costly corrections later.

Phase 3: Industrialization; millions of parts, zero surprises

The transition from development to full-scale production is where many manufacturing partnerships fall apart. Yield rates drop. Quality escapes appear. Lead times stretch. At RPK Medical, this transition is engineered, not hoped for.

With over 50 years of manufacturing experience and production facilities in Europe, the Americas, and Asia, RPK Medical delivers global industrialization with local accountability. Our ISO 7 clean rooms across all three regions ensure that high-volume production of springs, stamped components, and contact parts meets the same environmental and contamination-control standards as the development environment.

At an industrial scale, RPK Medical operates with:

• Quality control is built into the line. We use 100% unitary vision and control technology integrated directly into our assembly lines. Every part is inspected. Every anomaly is caught. There are no shortcuts based on sampling when patient safety is at stake.
• Full manufacturing services under one roof. From ultrasonic and biological cleaning to passivation, special coatings, surface treatments, welding, deburring, grinding, shot peening, and heat treatments, clients don't need to manage multiple suppliers across their spring and metal component supply chain. RPK Medical handles the full value chain.
• Rigorous product testing at our labs. Springs and metal components are tested for fatigue life, load relaxation, environmental performance, residual stress, dynamic behavior, and cleanliness, all at our in-house laboratories. This eliminates delays caused by third-party lab backlogs and keeps validation timelines in our hands.
• Custom packaging in clean room. We offer specialty packaging solutions,, including Tape & Reel and VCI formats, designed and executed in clean-room environments to maintain product integrity throughout the supply chain.

The outcome is a supply relationship in which pharma companies and CMOs can confidently plan around RPK Medical's production capacity, as the industrialization process was designed to be predictable from the start.

The RPK Technological Center: where global knowledge lives

Underpinning everything RPK Medical does is the RPK Technological Center, a dedicated facility that serves as the organization's technical brain. It is where new assembly line concepts are designed and tested before deployment in production. It is where complex challenges around spring design, multislide and stamping processes, and contact part engineering are solved. And critically, it is where knowledge is generated and shared in real time with engineering teams across RPK Medical's global network.

For clients, this means a solution developed for a European autoinjector program can inform and accelerate a similar program in the U.S. market. The learning compounds. The timelines shrink. The risk is lower.